MedPath
NMPA Approval

Rifandine Capsules

国药准字H36022137

July 16, 2022

国药准字H36022137

Drug Information

利福定胶囊

胶囊剂

0.15g

化学药品

July 16, 2022

Company Information

Applicant Company

江西省吉安市永丰县工业园南区

Manufacturing Company

江西省永丰县工业园南区

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

利福定胶囊 - NMPA 批准文号 | MedPath